{
  "release_id": "medyx-ema-observations-ccd58f8d7bd75733",
  "method": "documentary-families-1.0",
  "selection_rule": "One fully displayed content paragraph per Annex I section 4.1–4.9 and language; 20–1200 characters in both views; pairs differing only in whitespace excluded; medicine diversity; minimum SHA-256 of observation ID. Illustrative deterministic selection, not editorial or medical validation, not representative sampling.",
  "medical_validation": false,
  "observations": [
    {
      "observation_id": "change-40efe73fdfa72890c61df190",
      "medicine_id": "EMEA/H/C/000992",
      "section": "4.1",
      "language": "fr",
      "source_sha256": "359338f13851566c1b5a50785093846e9e52980167d40c4e41d57c7d5eda0080",
      "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/simponi-epar-product-information-tracked-changes_fr.docx",
      "path": "/donnees-originales/dossiers/simponi-4-1-fr-90c61df190/",
      "corpus_passage": "/donnees-originales/medicaments/simponi/page/2/#change-40efe73fdfa72890c61df190"
    },
    {
      "observation_id": "change-36e43a46a88a6c5252b8ee50",
      "medicine_id": "EMEA/H/C/000610",
      "section": "4.1",
      "language": "en",
      "source_sha256": "c04e50f3a55f2c8b60cd02dee87c8124ac98e6498185faaa13f3afcb3a098ecf",
      "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/noxafil-epar-product-information-tracked-changes_en.docx",
      "path": "/donnees-originales/dossiers/noxafil-4-1-en-5252b8ee50/",
      "corpus_passage": "/donnees-originales/medicaments/noxafil/page/2/#change-36e43a46a88a6c5252b8ee50"
    },
    {
      "observation_id": "change-4638ce9fabe9a92bda089acc",
      "medicine_id": "EMEA/H/C/002695",
      "section": "4.2",
      "language": "fr",
      "source_sha256": "835939e8841a039c75ad2b71ddde4acef2e5acd9a5e0a25b63e6774a75837088",
      "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/iclusig-epar-product-information-tracked-changes_fr.docx",
      "path": "/donnees-originales/dossiers/iclusig-4-2-fr-2bda089acc/",
      "corpus_passage": "/donnees-originales/medicaments/iclusig/#change-4638ce9fabe9a92bda089acc"
    },
    {
      "observation_id": "change-d1b0a826196a906e62fa9b83",
      "medicine_id": "EMEA/H/C/000955",
      "section": "4.2",
      "language": "en",
      "source_sha256": "cf4a91213ae92233c428a558204a83d1068aed134fdda1b1071732f361531aa2",
      "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/roactemra-epar-product-information-tracked-changes_en.docx",
      "path": "/donnees-originales/dossiers/roactemra-4-2-en-6e62fa9b83/",
      "corpus_passage": "/donnees-originales/medicaments/roactemra/page/15/#change-d1b0a826196a906e62fa9b83"
    },
    {
      "observation_id": "change-15628ea76f88aec24237a38b",
      "medicine_id": "EMEA/H/C/000306",
      "section": "4.3",
      "language": "fr",
      "source_sha256": "4460490d9e03b0eefa8f4ba217a5f17c9ea9d2e8df74a9d502b1098ff17e6408",
      "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/metalyse-epar-product-information-tracked-changes_fr.docx",
      "path": "/donnees-originales/dossiers/metalyse-4-3-fr-c24237a38b/",
      "corpus_passage": "/donnees-originales/medicaments/metalyse/#change-15628ea76f88aec24237a38b"
    },
    {
      "observation_id": "change-12c3e1771c710fcf319a4cd8",
      "medicine_id": "EMEA/H/C/002618",
      "section": "4.3",
      "language": "en",
      "source_sha256": "266d567343c3811aa2034b1a0d89c81f2a39f87634c27e040eddf35f3f1f5cac",
      "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/nexium-control-epar-product-information-tracked-changes_en.docx",
      "path": "/donnees-originales/dossiers/nexium-control-4-3-en-cf319a4cd8/",
      "corpus_passage": "/donnees-originales/medicaments/nexium-control/#change-12c3e1771c710fcf319a4cd8"
    },
    {
      "observation_id": "change-0e3c0d184172528f0894449f",
      "medicine_id": "EMEA/H/C/002294",
      "section": "4.4",
      "language": "fr",
      "source_sha256": "8d288ee6e274bde6c9200f061e223bc58547e51500d2908a8e2686bd8958ce69",
      "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_fr.docx",
      "path": "/donnees-originales/dossiers/vyndaqel-4-4-fr-8f0894449f/",
      "corpus_passage": "/donnees-originales/medicaments/vyndaqel/#change-0e3c0d184172528f0894449f"
    },
    {
      "observation_id": "change-8dc59932b5614372e476870b",
      "medicine_id": "EMEA/H/C/000235",
      "section": "4.4",
      "language": "en",
      "source_sha256": "2efff7967e2237bf8343431eef5e08b56c2441eb8a691a90c64b2635109fd697",
      "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_en.docx",
      "path": "/donnees-originales/dossiers/arava-4-4-en-72e476870b/",
      "corpus_passage": "/donnees-originales/medicaments/arava/#change-8dc59932b5614372e476870b"
    },
    {
      "observation_id": "change-26d0f589a6b1436ca3dfac2a",
      "medicine_id": "EMEA/H/C/003904",
      "section": "4.5",
      "language": "fr",
      "source_sha256": "1aa5801b5983595d59ac5834392591fabad217600cd1f35ffe8622c2f2623e51",
      "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/evotaz-epar-product-information-tracked-changes_fr.docx",
      "path": "/donnees-originales/dossiers/evotaz-4-5-fr-6ca3dfac2a/",
      "corpus_passage": "/donnees-originales/medicaments/evotaz/#change-26d0f589a6b1436ca3dfac2a"
    },
    {
      "observation_id": "change-46823aa3f5680fbfe16ca498",
      "medicine_id": "EMEA/H/C/005386",
      "section": "4.5",
      "language": "en",
      "source_sha256": "731d9e2cd6114fa554c8d21517a3b069ac619f60e3b1e54370b6c0a8e711e058",
      "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/phesgo-epar-product-information-tracked-changes_en.docx",
      "path": "/donnees-originales/dossiers/phesgo-4-5-en-bfe16ca498/",
      "corpus_passage": "/donnees-originales/medicaments/phesgo/page/2/#change-46823aa3f5680fbfe16ca498"
    },
    {
      "observation_id": "change-eac404db76ec8aaeee805e21",
      "medicine_id": "EMEA/H/C/000943",
      "section": "4.6",
      "language": "fr",
      "source_sha256": "cb49bf7246b5a91a36696e5747d9484abf0983e384c054ccf4a404dde191682f",
      "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/kuvan-epar-product-information-tracked-changes_fr.docx",
      "path": "/donnees-originales/dossiers/kuvan-4-6-fr-aeee805e21/",
      "corpus_passage": "/donnees-originales/medicaments/kuvan/#change-eac404db76ec8aaeee805e21"
    },
    {
      "observation_id": "change-ae547df27b615a7352136091",
      "medicine_id": "EMEA/H/C/005791",
      "section": "4.6",
      "language": "en",
      "source_sha256": "ee7712f3bea6ed1e7adb7ff4b59495e4c6961b92481d32d6b60668695c2bd753",
      "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/spikevax-epar-product-information-tracked-changes_en.docx",
      "path": "/donnees-originales/dossiers/spikevax-previously-covid-19-vaccine-moderna-4-6-en-7352136091/",
      "corpus_passage": "/donnees-originales/medicaments/spikevax-previously-covid-19-vaccine-moderna/#change-ae547df27b615a7352136091"
    },
    {
      "observation_id": "change-8984cbb6536151692e95d7e5",
      "medicine_id": "EMEA/H/C/000107",
      "section": "4.7",
      "language": "fr",
      "source_sha256": "904a2bee5f9c3c7a487325fb08ed809c65fa98667b82cab8453987f0747cdd99",
      "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/epivir-epar-product-information-tracked-changes_fr.docx",
      "path": "/donnees-originales/dossiers/epivir-4-7-fr-692e95d7e5/",
      "corpus_passage": "/donnees-originales/medicaments/epivir/#change-8984cbb6536151692e95d7e5"
    },
    {
      "observation_id": "change-fb632e801d85edc6d5e0400a",
      "medicine_id": "EMEA/H/C/000150",
      "section": "4.7",
      "language": "en",
      "source_sha256": "14e2ad0fbbfd646c637558259828d008457ab7ef3679c62fc1f9badc23c958f7",
      "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/quadramet-epar-product-information-tracked-changes_en.docx",
      "path": "/donnees-originales/dossiers/quadramet-4-7-en-c6d5e0400a/",
      "corpus_passage": "/donnees-originales/medicaments/quadramet/page/4/#change-fb632e801d85edc6d5e0400a"
    },
    {
      "observation_id": "change-ef9ef98b1a72e99fed877649",
      "medicine_id": "EMEA/H/C/000958",
      "section": "4.8",
      "language": "fr",
      "source_sha256": "36cb13a54d5f0df5b6079c2519692ebf03eafdbb7ada52f141382055515c3f2d",
      "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/stelara-epar-product-information-tracked-changes_fr.docx",
      "path": "/donnees-originales/dossiers/stelara-4-8-fr-9fed877649/",
      "corpus_passage": "/donnees-originales/medicaments/stelara/#change-ef9ef98b1a72e99fed877649"
    },
    {
      "observation_id": "change-25975b46edabf12acd001220",
      "medicine_id": "EMEA/H/C/006016",
      "section": "4.8",
      "language": "en",
      "source_sha256": "82f0e8242ee995348d54ec34bfb83b1be80ea917a347d059c060033f40386298",
      "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/imjudo-epar-product-information-tracked-changes_en.docx",
      "path": "/donnees-originales/dossiers/imjudo-4-8-en-2acd001220/",
      "corpus_passage": "/donnees-originales/medicaments/imjudo/#change-25975b46edabf12acd001220"
    },
    {
      "observation_id": "change-151258af84bbe241f9500b5a",
      "medicine_id": "EMEA/H/C/002389",
      "section": "4.9",
      "language": "fr",
      "source_sha256": "990d83ef143daea413153a5d1e5b9b4e44f929105e709d49547e55fc2c69676e",
      "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/kadcyla-epar-product-information-tracked-changes_fr.docx",
      "path": "/donnees-originales/dossiers/kadcyla-4-9-fr-41f9500b5a/",
      "corpus_passage": "/donnees-originales/medicaments/kadcyla/page/2/#change-151258af84bbe241f9500b5a"
    },
    {
      "observation_id": "change-8b558d8ca3166e01268aac85",
      "medicine_id": "EMEA/H/C/000229",
      "section": "4.9",
      "language": "en",
      "source_sha256": "7a0f4edca25a87307b3f79eb3b20278437df85acae9f08407579e07b880d9509",
      "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/temodal-epar-product-information-tracked-changes_en.docx",
      "path": "/donnees-originales/dossiers/temodal-4-9-en-01268aac85/",
      "corpus_passage": "/donnees-originales/medicaments/temodal/#change-8b558d8ca3166e01268aac85"
    }
  ]
}